Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Immix Biopharma ( (IMMX) ).
Immix Biopharma, Inc. has updated its consents from KMJ Corbin & Company LLP and Crowe LLP, its former and current independent registered public accounting firms, respectively. These updates, dated November 26, 2025, pertain to the incorporation of their reports into the company’s Registration Statement, reflecting the consolidated financial statements for the year ended December 31, 2024.
The most recent analyst rating on (IMMX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Average Trading Volume: 529,369
Technical Sentiment Signal: Buy
Current Market Cap: $144.4M
For a thorough assessment of IMMX stock, go to TipRanks’ Stock Analysis page.